RISA Labs: Redefining Cancer Care with an AI Operating System That Accelerates Treatment and Saves Lives

Cancer isn’t just a biological battle — it’s an operational one. For countless patients, the longest wait isn’t for therapy to work — it’s for care to begin. RISA Labs is changing that narrative by building an AI-driven operating system that eliminates the administrative bottlenecks slowing down cancer treatment nationwide.

A New Frontier in Oncology Operations

Founded by Kshitij Jaggi (CEO) and Kumar Shivang (CTO), RISA Labs is a Palo Alto–based healthtech startup on a mission to streamline complex oncology workflows that traditionally bog down clinicians and delay patient care. What started as a bold vision to tackle treatment delays is now turning into a scalable platform that is reshaping cancer care delivery across the U.S.

The Problem: Administrative Friction Costs Time — and Lives

One of the largest barriers in modern oncology isn’t clinical complexity — it’s administrative overhead. Processes like benefits verification, payer interaction, and prior authorization are still handled manually in many healthcare settings, costing valuable days in the patient journey. In oncology, where every day truly matters, those delays can negatively impact outcomes and elevate stress for both patients and care teams.

The Solution: BOSS — An AI Operating System Built for Healthcare

RISA Labs’ flagship product is called BOSS (Business Operating System as a Service) — a first-of-its-kind AI operating layer designed to coordinate mission-critical workflows across fragmented healthcare software stacks. By connecting directly to electronic medical records (EMRs), payer portals, and benefits systems, BOSS orchestrates complex tasks that once required manual intervention.

What BOSS Does

• AI Agents that Read, Reason & Act — The system interprets unstructured data, navigates forms, and executes tasks across multiple platforms.

• Automated Prior Authorization — From days to hours: authorization workflows that used to take up to eight days can now be completed within 24 hours or less.

• Reduced Errors and Denials — Early deployments show denials dropping by up to 40% and first-pass approval rates nearing 98%.

• Efficiency Gains — Staff can reallocate time previously spent on paperwork toward higher-value clinical duties.

At partner oncology practices, RISA’s technology has reduced administrative workload by approximately 80%, dramatically accelerated authorization timelines, and enabled clinics to serve more patients without expanding headcount.

Strategic Funding Signals Confidence and Momentum

$3.5M Seed Round (2025)

In April 2025, RISA Labs raised a $3.5 million seed round led by Binny Bansal, co-founder of Flipkart, with participation from Oncology Ventures, General Catalyst, z21 Ventures, and others. This initial capital fueled early development of BOSS and supported deployments across cancer centers nationwide.

$11.1M Series A (January 2026)

In the biggest milestone to date, RISA Labs closed an $11.1 million Series A financing in early 2026. The round was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, and John Simon’s Ventureforgood.

This influx of capital will accelerate nationwide deployment of RISA’s AI operating system across cancer clinics, health systems, specialty pharmacies, and infusion networks — expanding its reach and operational impact in oncology workflows.

Investors cited the urgent need for solutions that optimize both access and capacity in cancer care, particularly as treatment protocols grow more complex and healthcare staffing remains constrained.

Why RISA’s Approach Matters

RISA Labs’ technology tackles the structural problems that have long plagued healthcare administration:

• Fewer Delays, Faster Care: By reducing time spent on approvals and verifications, patients can begin treatment sooner.

• Clinician Empowerment: Automating administrative workload lets healthcare teams focus on clinical judgement and patient interaction.

• Operational Insights: The platform provides transparent, auditable workflows that give organizations insights into performance and compliance.

In a sector where timeliness can be as critical as therapy choice, RISA Labs is enabling healthcare providers to move faster and more deliberately — ensuring that the promise of modern medicine isn’t delayed by paperwork.

Looking Ahead

RISA Labs remains tightly focused on oncology for now, but its underlying AI operating system — built for complex workflow automation — has broader implications across healthcare and beyond. With strong financial backing and real-world impact metrics already emerging, RISA is poised to become a benchmark for how AI can meaningfully augment institutional operations.